Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ET-01 in Transfusion Dependent Beta-Thalassemia
NCT05752123Phase 1Terminated
- Sponsor
- EdiGene Inc.
- Start
- Feb 2023
- Primary completion
- Jan 2024
- Modality
- CRISPR-Cas9, Gene Silencing, Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ET-01 in beta thalassemia, sponsored by EdiGene Inc. Primary endpoints: Adverse Events and Serious Adverse Events at 104 weeks, All-cause mortality at 104 weeks and 2 more. Started Feb 2023; status: terminated.
02
Drugs
ET-01
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT05752123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05752123.